-1.14 %
+9.83 %
+2.70 %
-6.86 %
-6.86 %
+49.02 %
-4.04 %
-32.28 %
-81.14 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
50.36M EUR
Turnover
13.52K EUR
P/E (adj.) (26e)
-15.43
EV/EBIT (adj.) (26e)
-13.75
P/B (26e)
6.48
EV/S (26e)
5,622.1
Dividend yield-% (26e)
-
